HRP20110520T1 - Acilaminopirazoli kao inhibitori fgfr - Google Patents
Acilaminopirazoli kao inhibitori fgfr Download PDFInfo
- Publication number
- HRP20110520T1 HRP20110520T1 HR20110520T HRP20110520T HRP20110520T1 HR P20110520 T1 HRP20110520 T1 HR P20110520T1 HR 20110520 T HR20110520 T HR 20110520T HR P20110520 T HRP20110520 T HR P20110520T HR P20110520 T1 HRP20110520 T1 HR P20110520T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazol
- ethyl
- dimethoxyphenyl
- benzamide
- hydroxyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims abstract 87
- 150000002367 halogens Chemical class 0.000 claims abstract 87
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 85
- 125000001424 substituent group Chemical group 0.000 claims abstract 81
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims abstract 59
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 55
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 54
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 34
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 6
- 239000001301 oxygen Chemical group 0.000 claims abstract 6
- 229910052717 sulfur Chemical group 0.000 claims abstract 6
- 239000011593 sulfur Chemical group 0.000 claims abstract 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 57
- 229910052739 hydrogen Inorganic materials 0.000 claims 47
- 239000001257 hydrogen Substances 0.000 claims 47
- 150000002431 hydrogen Chemical class 0.000 claims 43
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 13
- -1 C3-cycloalkyl Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 9
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 8
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 7
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- BYNNMWGWFIGTIC-LLVKDONJSA-N (2r)-3-naphthalen-1-yloxypropane-1,2-diol Chemical compound C1=CC=C2C(OC[C@H](O)CO)=CC=CC2=C1 BYNNMWGWFIGTIC-LLVKDONJSA-N 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- PFZTXTPVKAGHPW-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CC(C)N(C)CC3)C=2)=C1 PFZTXTPVKAGHPW-UHFFFAOYSA-N 0.000 claims 2
- BPELTTMGJQPXIY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[(3-fluoropiperidin-1-yl)methyl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CN4CC(F)CCC4)=CC=3)C=2)=C1 BPELTTMGJQPXIY-UHFFFAOYSA-N 0.000 claims 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 2
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims 2
- SJSSFUMSAFMFNM-NSHDSACASA-N (2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 SJSSFUMSAFMFNM-NSHDSACASA-N 0.000 claims 1
- SOIIHESTBYNJRH-PMPSAXMXSA-N (3r,6r,8as)-6-(benzylsulfonylamino)-n-[3-(diaminomethylideneamino)propyl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide Chemical compound N([C@@H]1CC[C@@H]2SC[C@H](N2C1=O)C(=O)NCCCN=C(N)N)S(=O)(=O)CC1=CC=CC=C1 SOIIHESTBYNJRH-PMPSAXMXSA-N 0.000 claims 1
- RXBMEHOLQJITJI-LEOXJPRUSA-N (4s)-5-amino-4-[[(2s)-2-[[(2s)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-(3-phenyl-1,2-oxazol-5-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N)CP(O)(=O)C=1C=CC(Br)=CC=1)C(ON=1)=CC=1C1=CC=CC=C1 RXBMEHOLQJITJI-LEOXJPRUSA-N 0.000 claims 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims 1
- FRZNJFWQVYAVCE-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)phenyl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=CC(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 FRZNJFWQVYAVCE-UHFFFAOYSA-N 0.000 claims 1
- PJAKRMBXANCRRH-UHFFFAOYSA-N 2-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC4CCCCN4CC3)=C2)=C1 PJAKRMBXANCRRH-UHFFFAOYSA-N 0.000 claims 1
- LZZYDLADMOQZTD-UHFFFAOYSA-N 2-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC4CCCCN4CC3)=C2)=C1 LZZYDLADMOQZTD-UHFFFAOYSA-N 0.000 claims 1
- XIFCRKATKAZDEQ-UHFFFAOYSA-N 2-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC4CCCN4CC3)=C2)=C1 XIFCRKATKAZDEQ-UHFFFAOYSA-N 0.000 claims 1
- SAXDDBYCUJXAIQ-UHFFFAOYSA-N 2-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC4CCCN4CC3)=C2)=C1 SAXDDBYCUJXAIQ-UHFFFAOYSA-N 0.000 claims 1
- GSZMBOOFYZJXIE-UHFFFAOYSA-N 2-(4-cyclopropyl-1,4-diazepan-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(CCC3)C3CC3)=C2)=C1 GSZMBOOFYZJXIE-UHFFFAOYSA-N 0.000 claims 1
- YPHOYQVYSBBIRC-UHFFFAOYSA-N 2-(4-cyclopropylpiperazin-1-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(CC3)C3CC3)=C2)=C1 YPHOYQVYSBBIRC-UHFFFAOYSA-N 0.000 claims 1
- IDPLQWNTAFBGOW-UHFFFAOYSA-N 2-(4-cyclopropylpiperazin-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(CC3)C3CC3)=C2)=C1 IDPLQWNTAFBGOW-UHFFFAOYSA-N 0.000 claims 1
- JKKOLPWDKQDVJE-UHFFFAOYSA-N 3-[(3-fluoro-4-methoxyphenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound C1=C(F)C(OC)=CC=C1CNC1=NC2=CC(C(F)(F)F)=CC=C2N=C1C(O)=O JKKOLPWDKQDVJE-UHFFFAOYSA-N 0.000 claims 1
- APJAEXGNDLFGPD-AWCRTANDSA-N 3-amino-n-{4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-1-isobutyl-5-phenyl-pentyl}-benzamide Chemical group C([C@@H]([C@@H](O)C[C@H](CC(C)C)NC(=O)C=1C=CC(N)=CC=1)NC(=O)COC=1C(=CC=CC=1C)C)C1=CC=CC=C1 APJAEXGNDLFGPD-AWCRTANDSA-N 0.000 claims 1
- NHSNMCZCQCZMKT-UHFFFAOYSA-N 4-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC4NCCCC4C3)=C2)=C1 NHSNMCZCQCZMKT-UHFFFAOYSA-N 0.000 claims 1
- CHSSXTHDKLNKJR-UHFFFAOYSA-N 4-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC4CCCCN4CC3)=C2)=C1 CHSSXTHDKLNKJR-UHFFFAOYSA-N 0.000 claims 1
- ZYLKUSYOAFZPDW-UHFFFAOYSA-N 4-(1,4-diazepan-1-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCNCCC3)C=2)=C1 ZYLKUSYOAFZPDW-UHFFFAOYSA-N 0.000 claims 1
- VQZLJZIEDTZTQJ-UHFFFAOYSA-N 4-(1-cyclopropylpiperidin-4-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)C3CCN(CC3)C3CC3)=C2)=C1 VQZLJZIEDTZTQJ-UHFFFAOYSA-N 0.000 claims 1
- NPPNBNZVHZLBMR-UHFFFAOYSA-N 4-(2-aminopropyl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CC(C)N)=CC=3)C=2)=C1 NPPNBNZVHZLBMR-UHFFFAOYSA-N 0.000 claims 1
- AJRZAIWDKUDXTA-UHFFFAOYSA-N 4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC4CCCN4CC3)=C2)=C1 AJRZAIWDKUDXTA-UHFFFAOYSA-N 0.000 claims 1
- FILOJIFKRJXQCS-UHFFFAOYSA-N 4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC4CCCN4CC3)=C2)=C1 FILOJIFKRJXQCS-UHFFFAOYSA-N 0.000 claims 1
- CKNIRFFXNOGDAM-UHFFFAOYSA-N 4-(4-acetylpiperazin-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C(C)=O)C=2)=C1 CKNIRFFXNOGDAM-UHFFFAOYSA-N 0.000 claims 1
- CPYWICDXAPUQNJ-UHFFFAOYSA-N 4-(4-cyclobutylpiperazin-1-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C3CCC3)=C2)=C1 CPYWICDXAPUQNJ-UHFFFAOYSA-N 0.000 claims 1
- LHCIFVUABPXLJF-UHFFFAOYSA-N 4-(4-cyclobutylpiperazin-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C3CCC3)C=2)=C1 LHCIFVUABPXLJF-UHFFFAOYSA-N 0.000 claims 1
- REPFWMXEYOBBGF-UHFFFAOYSA-N 4-(4-cyclopropyl-1,4-diazepan-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CCC3)C3CC3)=C2)=C1 REPFWMXEYOBBGF-UHFFFAOYSA-N 0.000 claims 1
- FICSDJQCXTVTCL-UHFFFAOYSA-N 4-(4-cyclopropylpiperazin-1-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C3CC3)=C2)=C1 FICSDJQCXTVTCL-UHFFFAOYSA-N 0.000 claims 1
- GPJKIUMNZAQZFH-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[5-(2-phenylethyl)-1h-pyrazol-3-yl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=CC=CC=3)C=2)C=C1 GPJKIUMNZAQZFH-UHFFFAOYSA-N 0.000 claims 1
- GEMFRLOKPQVJLT-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[5-(2-pyridin-3-ylethyl)-1h-pyrazol-3-yl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=NC=CC=3)C=2)C=C1 GEMFRLOKPQVJLT-UHFFFAOYSA-N 0.000 claims 1
- DPRSWOBINUHRTN-UHFFFAOYSA-N 4-(hydroxymethyl)-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(CO)=CC=3)=C2)=C1 DPRSWOBINUHRTN-UHFFFAOYSA-N 0.000 claims 1
- MMYHYVFABXWZGF-UHFFFAOYSA-N 4-(methanesulfonamido)-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(NS(C)(=O)=O)=CC=3)=C2)=C1 MMYHYVFABXWZGF-UHFFFAOYSA-N 0.000 claims 1
- KWECWVXCPHIAFO-UHFFFAOYSA-N 4-[(7-cyano-3,4-dihydro-1h-isoquinolin-2-yl)methyl]-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CN4CC5=CC(=CC=C5CC4)C#N)=CC=3)C=2)=C1 KWECWVXCPHIAFO-UHFFFAOYSA-N 0.000 claims 1
- VVBRWELWMMRIGM-UHFFFAOYSA-N 4-[2-(4,4-difluoropiperidin-1-yl)ethoxy]-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(OCCN4CCC(F)(F)CC4)=CC=3)C=2)=C1 VVBRWELWMMRIGM-UHFFFAOYSA-N 0.000 claims 1
- BUYUFJZVMVFQLQ-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydroquinoxalin-2-yl)ethynyl]benzoic acid Chemical compound CC1(C=2N=CC(=NC=2C(CC1)(C)C)C#CC1=CC=C(C(=O)O)C=C1)C BUYUFJZVMVFQLQ-UHFFFAOYSA-N 0.000 claims 1
- JCNUWWFTYZKKMO-UHFFFAOYSA-N 4-acetamido-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(NC(C)=O)=CC=3)=C2)=C1 JCNUWWFTYZKKMO-UHFFFAOYSA-N 0.000 claims 1
- WQUBEIMCFHCJCO-AWCRTANDSA-N 4-amino-n-{4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-1-isobutyl-5-phenyl-pentyl}-benzamide Chemical group C([C@@H]([C@@H](O)C[C@H](CC(C)C)NC(=O)C=1C=C(N)C=CC=1)NC(=O)COC=1C(=CC=CC=1C)C)C1=CC=CC=C1 WQUBEIMCFHCJCO-AWCRTANDSA-N 0.000 claims 1
- UXVZRJOTGSEMKR-UHFFFAOYSA-N 4-benzamido-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(NC(=O)C=4C=CC=CC=4)=CC=3)=C2)=C1 UXVZRJOTGSEMKR-UHFFFAOYSA-N 0.000 claims 1
- KNJZJTPWIMKMLS-UHFFFAOYSA-N 4-cyano-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)C#N)=C2)=C1 KNJZJTPWIMKMLS-UHFFFAOYSA-N 0.000 claims 1
- RSLUCSKUCDYSQI-UHFFFAOYSA-N 4-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzene-1,4-dicarboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)C(N)=O)=C2)=C1 RSLUCSKUCDYSQI-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- ZAFKNYDURSJKQP-UHFFFAOYSA-N 5-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC4CCCCN4CC3)=C2)=C1 ZAFKNYDURSJKQP-UHFFFAOYSA-N 0.000 claims 1
- DTNXPDAEHCDVIB-UHFFFAOYSA-N 5-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC4CCCCN4CC3)=C2)=C1 DTNXPDAEHCDVIB-UHFFFAOYSA-N 0.000 claims 1
- WHUJVYOGWOQXJA-UHFFFAOYSA-N 5-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC4CCCN4CC3)=C2)=C1 WHUJVYOGWOQXJA-UHFFFAOYSA-N 0.000 claims 1
- DMVGEABLDWSSRT-UHFFFAOYSA-N 5-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3SC(=CC=3)N3CC4CCCN4CC3)=C2)=C1 DMVGEABLDWSSRT-UHFFFAOYSA-N 0.000 claims 1
- AABBJGRKPVKZBZ-UHFFFAOYSA-N 5-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC4CCCN4CC3)=C2)=C1 AABBJGRKPVKZBZ-UHFFFAOYSA-N 0.000 claims 1
- WIYZJAWGAMJTGS-UHFFFAOYSA-N 5-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3SC(=CC=3)N3CC4CCCN4CC3)=C2)=C1 WIYZJAWGAMJTGS-UHFFFAOYSA-N 0.000 claims 1
- DKMXLWLZNWCMCI-UHFFFAOYSA-N 5-(4-cyclopropyl-1,4-diazepan-1-yl)-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(CCC3)C3CC3)=C2)=C1 DKMXLWLZNWCMCI-UHFFFAOYSA-N 0.000 claims 1
- NMMYWKWTRBUURS-UHFFFAOYSA-N 5-(4-cyclopropylpiperazin-1-yl)-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(CC3)C3CC3)=C2)=C1 NMMYWKWTRBUURS-UHFFFAOYSA-N 0.000 claims 1
- PKXJQHUMHSTQSA-CALCHBBNSA-N 5-[(3s,5r)-4-(cyanomethyl)-3,5-dimethylpiperazin-1-yl]-n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3C[C@@H](C)N(CC#N)[C@@H](C)C3)=C2)=C1 PKXJQHUMHSTQSA-CALCHBBNSA-N 0.000 claims 1
- PPHUZVJANIVFJQ-HDICACEKSA-N 5-[(3s,5r)-4-(cyanomethyl)-3,5-dimethylpiperazin-1-yl]-n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3C[C@@H](C)N(CC#N)[C@@H](C)C3)=C2)=C1 PPHUZVJANIVFJQ-HDICACEKSA-N 0.000 claims 1
- HRCNSDLFNYOODP-UHFFFAOYSA-N 5-[[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]pyridine-2-carboxylic acid Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(=CC=3)C(O)=O)=C2)=C1 HRCNSDLFNYOODP-UHFFFAOYSA-N 0.000 claims 1
- JMSZVABYDKIGIA-UHFFFAOYSA-N 5-formamido-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-2-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3N=CC(NC=O)=CC=3)=C2)=C1 JMSZVABYDKIGIA-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- NCTHHJRIJGFPTG-UHFFFAOYSA-N 6,7-bis(aziridin-1-yl)-4-[7-[[6,7-bis(aziridin-1-yl)-5,8-dioxoquinazolin-4-yl]amino]heptylamino]quinazoline-5,8-dione Chemical compound C1CN1C=1C(=O)C2=C(NCCCCCCCNC=3C=4C(=O)C(N5CC5)=C(N5CC5)C(=O)C=4N=CN=3)N=CN=C2C(=O)C=1N1CC1 NCTHHJRIJGFPTG-UHFFFAOYSA-N 0.000 claims 1
- YZUNCEWXBIYTFT-UHFFFAOYSA-N 6-(2-methoxyethoxy)-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound C1=NC(OCCOC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=CC=2)=NN1 YZUNCEWXBIYTFT-UHFFFAOYSA-N 0.000 claims 1
- ZSKOTTDPJUEZJX-UHFFFAOYSA-N 6-(ethylamino)-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound C1=NC(NCC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=CC=2)=NN1 ZSKOTTDPJUEZJX-UHFFFAOYSA-N 0.000 claims 1
- ZHDHSBKTLRLUCQ-UHFFFAOYSA-N 6-[4-(6-bromo-1,2-benzothiazol-3-yl)phenoxy]-n-methyl-n-prop-2-enylhexan-1-amine Chemical compound C1=CC(OCCCCCCN(C)CC=C)=CC=C1C1=NSC2=CC(Br)=CC=C12 ZHDHSBKTLRLUCQ-UHFFFAOYSA-N 0.000 claims 1
- KETBCMTYHZNGEV-UHFFFAOYSA-N 6-anilino-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(NC=4C=CC=CC=4)=CC=3)=C2)=C1 KETBCMTYHZNGEV-UHFFFAOYSA-N 0.000 claims 1
- DOVOTUJDSHELKJ-UHFFFAOYSA-N 6-chloro-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(Cl)=CC=3)=C2)=C1 DOVOTUJDSHELKJ-UHFFFAOYSA-N 0.000 claims 1
- PTEJDKGWDNPCNH-UHFFFAOYSA-N 6-cyano-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(=CC=3)C#N)=C2)=C1 PTEJDKGWDNPCNH-UHFFFAOYSA-N 0.000 claims 1
- WCYYXYDRJSKZOD-UHFFFAOYSA-N 6-methoxy-n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(OC)=CC=3)=C2)=C1 WCYYXYDRJSKZOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- ZOUTYVWHWSUKPL-RNCFNFMXSA-N C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical compound C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZOUTYVWHWSUKPL-RNCFNFMXSA-N 0.000 claims 1
- DSODRWWHAUGSGD-UHFFFAOYSA-N [5-(carbamimidoylsulfanylmethyl)thiophen-2-yl]methyl carbamimidothioate;dihydrochloride Chemical compound Cl.Cl.NC(=N)SCC1=CC=C(CSC(N)=N)S1 DSODRWWHAUGSGD-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- LBDQPXFVZSAJPM-UHFFFAOYSA-N ethyl 5-[[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OCC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=CC=2)=NN1 LBDQPXFVZSAJPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NJMBQRNWBHNVOZ-UHFFFAOYSA-N methyl 5-[[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=CC=2)=NN1 NJMBQRNWBHNVOZ-UHFFFAOYSA-N 0.000 claims 1
- YUVSEEWMRSXTRL-UHFFFAOYSA-N methyl 6-[[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=CC=2)=NN1 YUVSEEWMRSXTRL-UHFFFAOYSA-N 0.000 claims 1
- HTBHTRYNRHGOML-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-2-(3,4-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC(C)N(C)CC3)=C2)=C1 HTBHTRYNRHGOML-UHFFFAOYSA-N 0.000 claims 1
- KABBUICSDDSZHY-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(COC=2NN=C(NC(=O)C=3C=NC(=NC=3)N3CCN(C)CC3)C=2)=C1 KABBUICSDDSZHY-UHFFFAOYSA-N 0.000 claims 1
- BXUCLDIBYXBAKH-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-3-piperazin-1-ylbenzamide Chemical compound COC1=CC(OC)=CC(COC=2NN=C(NC(=O)C=3C=C(C=CC=3)N3CCNCC3)C=2)=C1 BXUCLDIBYXBAKH-UHFFFAOYSA-N 0.000 claims 1
- APPRGXHIUOWFLJ-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)C3CCN(C)CC3)=C2)=C1 APPRGXHIUOWFLJ-UHFFFAOYSA-N 0.000 claims 1
- KZTLOKUXUKISRM-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-(3,3-dimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC(C)(C)NCC3)=C2)=C1 KZTLOKUXUKISRM-UHFFFAOYSA-N 0.000 claims 1
- DFDRSTKZIRHZJZ-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC(C)N(C)CC3)=C2)=C1 DFDRSTKZIRHZJZ-UHFFFAOYSA-N 0.000 claims 1
- VTKDZLYDUNFECD-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-(4-ethylpiperazin-1-yl)benzamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)NC=2NN=C(OCC=3C=C(OC)C=C(OC)C=3)C=2)C=C1 VTKDZLYDUNFECD-UHFFFAOYSA-N 0.000 claims 1
- LYZMEFMTACWOAW-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 LYZMEFMTACWOAW-UHFFFAOYSA-N 0.000 claims 1
- ADTZRSTUJXIHGE-HDICACEKSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-[(3r,5s)-3,4,5-trimethylpiperazin-1-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N(C)[C@@H](C)C3)=C2)=C1 ADTZRSTUJXIHGE-HDICACEKSA-N 0.000 claims 1
- AKOUAKDGWAGIOY-CALCHBBNSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)=C2)=C1 AKOUAKDGWAGIOY-CALCHBBNSA-N 0.000 claims 1
- PQPZBQHFOADSEF-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-[2-(dimethylamino)ethylamino]benzamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=CC(NCCN(C)C)=CC=3)=C2)=C1 PQPZBQHFOADSEF-UHFFFAOYSA-N 0.000 claims 1
- RCMFWEPHBXSEJD-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC(OCC=2C=C(OC)C=C(OC)C=2)=NN1 RCMFWEPHBXSEJD-UHFFFAOYSA-N 0.000 claims 1
- VGRSGFKGDIBBDY-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(3,3-dimethylpiperazin-1-yl)thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3SC(=CC=3)N3CC(C)(C)NCC3)=C2)=C1 VGRSGFKGDIBBDY-UHFFFAOYSA-N 0.000 claims 1
- IKEAYQIGDUZGRU-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(3,4-dimethylpiperazin-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC(C)N(C)CC3)=C2)=C1 IKEAYQIGDUZGRU-UHFFFAOYSA-N 0.000 claims 1
- IHTGUNPCPCXBLL-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(3,4-dimethylpiperazin-1-yl)thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3SC(=CC=3)N3CC(C)N(C)CC3)=C2)=C1 IHTGUNPCPCXBLL-UHFFFAOYSA-N 0.000 claims 1
- VOXIVECESPVFBW-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(4-ethylpiperazin-1-yl)thiophene-2-carboxamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)NC=2NN=C(OCC=3C=C(OC)C=C(OC)C=3)C=2)S1 VOXIVECESPVFBW-UHFFFAOYSA-N 0.000 claims 1
- ZALAXLCSSNUIBI-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(4-methylpiperazin-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(C)CC3)=C2)=C1 ZALAXLCSSNUIBI-UHFFFAOYSA-N 0.000 claims 1
- BLYXFMYJELIOBF-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(4-methylpiperazin-1-yl)pyridine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 BLYXFMYJELIOBF-UHFFFAOYSA-N 0.000 claims 1
- PQOAVCZIWSDZRF-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-(4-methylpiperazin-1-yl)thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3SC(=CC=3)N3CCN(C)CC3)=C2)=C1 PQOAVCZIWSDZRF-UHFFFAOYSA-N 0.000 claims 1
- BZYIETPSKLUOBV-IYBDPMFKSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-[(3r,5s)-3,4,5-trimethylpiperazin-1-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3N=CC(=NC=3)N3C[C@@H](C)N(C)[C@@H](C)C3)=C2)=C1 BZYIETPSKLUOBV-IYBDPMFKSA-N 0.000 claims 1
- ZXQKDGVRECCNPW-GASCZTMLSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-5-[(3r,5s)-3,5-dimethylpiperazin-1-yl]thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3SC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)=C2)=C1 ZXQKDGVRECCNPW-GASCZTMLSA-N 0.000 claims 1
- BJKOXNCTKHXBQB-UHFFFAOYSA-N n-[3-[(3,5-dimethoxyphenyl)methoxy]-1h-pyrazol-5-yl]-6-piperazin-1-ylpyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC(COC2=NNC(NC(=O)C=3C=NC(=CC=3)N3CCNCC3)=C2)=C1 BJKOXNCTKHXBQB-UHFFFAOYSA-N 0.000 claims 1
- NZSWVTUNTOOPSX-UHFFFAOYSA-N n-[5-[2-(1,3-benzodioxol-5-yl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=C4OCOC4=CC=3)C=2)C=C1 NZSWVTUNTOOPSX-UHFFFAOYSA-N 0.000 claims 1
- CHHAULSRBCMTEH-UHFFFAOYSA-N n-[5-[2-(2,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound COC1=CC=C(OC)C(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 CHHAULSRBCMTEH-UHFFFAOYSA-N 0.000 claims 1
- XQOCOFYGTCSAOM-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)C3CCN(C)CC3)=C2)=C1 XQOCOFYGTCSAOM-UHFFFAOYSA-N 0.000 claims 1
- FVNRGESZWOWIOE-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(3,4-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC(C)N(C)CC3)=C2)=C1 FVNRGESZWOWIOE-UHFFFAOYSA-N 0.000 claims 1
- CZXNOIODNKWIMD-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-ethyl-1,4-diazepan-1-yl)pyrimidine-5-carboxamide Chemical compound C1CN(CC)CCCN1C1=NC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=N1 CZXNOIODNKWIMD-UHFFFAOYSA-N 0.000 claims 1
- FAHBNVACFBFOJF-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-ethyl-3-methylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound C1C(C)N(CC)CCN1C1=NC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=N1 FAHBNVACFBFOJF-UHFFFAOYSA-N 0.000 claims 1
- MXXLFRNLGXFBFX-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-methyl-1,4-diazepan-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(C)CCC3)=C2)=C1 MXXLFRNLGXFBFX-UHFFFAOYSA-N 0.000 claims 1
- MJXRPIUNMFYPIO-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-methyl-3-oxopiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CC(=O)N(C)CC3)=C2)=C1 MJXRPIUNMFYPIO-UHFFFAOYSA-N 0.000 claims 1
- SBOMLRJHYLXHOT-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(C)CC3)=C2)=C1 SBOMLRJHYLXHOT-UHFFFAOYSA-N 0.000 claims 1
- BLSDFZNQLNQDHA-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-prop-2-enyl-1,4-diazepan-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(CC=C)CCC3)=C2)=C1 BLSDFZNQLNQDHA-UHFFFAOYSA-N 0.000 claims 1
- DVALSWWLWJAYFA-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-(4-propan-2-yl-1,4-diazepan-1-yl)pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3CCN(CCC3)C(C)C)=C2)=C1 DVALSWWLWJAYFA-UHFFFAOYSA-N 0.000 claims 1
- BZGVWXWWPSHTMZ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-[(3-methyl-1,2-oxazol-5-yl)methylamino]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C(=CC=CC=3)NCC=3ON=C(C)C=3)C=2)=C1 BZGVWXWWPSHTMZ-UHFFFAOYSA-N 0.000 claims 1
- VHIJSBLWIJRAQN-CALCHBBNSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-[(3r,5s)-3,4,5-trimethylpiperazin-1-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3C[C@@H](C)N(C)[C@@H](C)C3)=C2)=C1 VHIJSBLWIJRAQN-CALCHBBNSA-N 0.000 claims 1
- NSMXFXVYCUXPCS-JOCHJYFZSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-[(3s)-3-propan-2-ylpiperazin-1-yl]pyrimidine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=NC(=NC=3)N3C[C@@H](NCC3)C(C)C)=C2)=C1 NSMXFXVYCUXPCS-JOCHJYFZSA-N 0.000 claims 1
- NBGAVLHIQQGGBW-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-[3-(methoxymethyl)piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound C1CNC(COC)CN1C1=NC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=N1 NBGAVLHIQQGGBW-UHFFFAOYSA-N 0.000 claims 1
- RZDKJOIXLSDHEY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-2-methoxybenzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C(=CC=CC=3)OC)C=2)=C1 RZDKJOIXLSDHEY-UHFFFAOYSA-N 0.000 claims 1
- NRPNSWGFZFIPKX-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC2=NNC(CCC=3C=C(OC)C=C(OC)C=3)=C2)=C1 NRPNSWGFZFIPKX-UHFFFAOYSA-N 0.000 claims 1
- PKQMCBZGVQXASK-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-3-morpholin-4-ylbenzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=C(C=CC=3)N3CCOCC3)C=2)=C1 PKQMCBZGVQXASK-UHFFFAOYSA-N 0.000 claims 1
- BVJBIYYANCOBPH-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(1-ethylpiperidin-4-yl)benzamide Chemical compound C1CN(CC)CCC1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=C1 BVJBIYYANCOBPH-UHFFFAOYSA-N 0.000 claims 1
- QEAUOXZTRVBQEI-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)C3CCN(C)CC3)C=2)=C1 QEAUOXZTRVBQEI-UHFFFAOYSA-N 0.000 claims 1
- KJHGWDAUJWJTCZ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(1-prop-2-enylpiperidin-4-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)C3CCN(CC=C)CC3)=C2)=C1 KJHGWDAUJWJTCZ-UHFFFAOYSA-N 0.000 claims 1
- DPYYBBUVHIZEPV-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(2-hydroxyethoxy)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(OCCO)=CC=3)C=2)=C1 DPYYBBUVHIZEPV-UHFFFAOYSA-N 0.000 claims 1
- RQQHNJWGOVRQNJ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(OCCN4CCOCC4)=CC=3)C=2)=C1 RQQHNJWGOVRQNJ-UHFFFAOYSA-N 0.000 claims 1
- OLOIRPDQVXBXAY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(2-morpholin-4-ylethyl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CCN4CCOCC4)=CC=3)C=2)=C1 OLOIRPDQVXBXAY-UHFFFAOYSA-N 0.000 claims 1
- OFPZHPFNAAUZHU-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,3-dimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC(C)(C)NCC3)=C2)=C1 OFPZHPFNAAUZHU-UHFFFAOYSA-N 0.000 claims 1
- WCSHYWQDZXNEEQ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4,5-trimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CC(C)N(C)C(C)C3)C=2)=C1 WCSHYWQDZXNEEQ-UHFFFAOYSA-N 0.000 claims 1
- VRQMAABPASPXMW-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CC(C)NC(C)C3)=C2)=C1 VRQMAABPASPXMW-UHFFFAOYSA-N 0.000 claims 1
- UECZYORGLPLSJC-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-ethyl-1,4-diazepan-1-yl)benzamide Chemical compound C1CN(CC)CCCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=C1 UECZYORGLPLSJC-UHFFFAOYSA-N 0.000 claims 1
- UJJSGJULFHMHMJ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=C1 UJJSGJULFHMHMJ-UHFFFAOYSA-N 0.000 claims 1
- WTLALQRLHBXTHM-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CCC3)=C2)=C1 WTLALQRLHBXTHM-UHFFFAOYSA-N 0.000 claims 1
- PAOGAOWJMITTAC-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 PAOGAOWJMITTAC-UHFFFAOYSA-N 0.000 claims 1
- KTFGJFQSPXGZHE-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazine-1-carbonyl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)C(=O)N3CCN(C)CC3)C=2)=C1 KTFGJFQSPXGZHE-UHFFFAOYSA-N 0.000 claims 1
- WVIFYEUDNSJDCL-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-prop-2-enyl-1,4-diazepan-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CC=C)CCC3)=C2)=C1 WVIFYEUDNSJDCL-UHFFFAOYSA-N 0.000 claims 1
- KJPXHCOJCLZPHO-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-propan-2-yl-1,4-diazepan-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CCC3)C(C)C)=C2)=C1 KJPXHCOJCLZPHO-UHFFFAOYSA-N 0.000 claims 1
- OLTKVTPQMIIGOU-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-propan-2-ylpiperazin-1-yl)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C(C)C)C=2)=C1 OLTKVTPQMIIGOU-UHFFFAOYSA-N 0.000 claims 1
- GLVDAZNVZRUWAW-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(dimethylamino)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N(C)C)C=2)=C1 GLVDAZNVZRUWAW-UHFFFAOYSA-N 0.000 claims 1
- KPPCOCFKMSKIOU-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(piperidin-4-ylmethoxy)benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(OCC4CCNCC4)=CC=3)C=2)=C1 KPPCOCFKMSKIOU-UHFFFAOYSA-N 0.000 claims 1
- WCSHYWQDZXNEEQ-KDURUIRLSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[(3s,5r)-3,4,5-trimethylpiperazin-1-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N(C)[C@@H](C)C3)=C2)=C1 WCSHYWQDZXNEEQ-KDURUIRLSA-N 0.000 claims 1
- OYAIBFUSEDTFIX-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CN4CCN(C)CC4)=CC=3)C=2)=C1 OYAIBFUSEDTFIX-UHFFFAOYSA-N 0.000 claims 1
- SRVZIPFKDSFEGJ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[(dimethylamino)methyl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CN(C)C)=CC=3)C=2)=C1 SRVZIPFKDSFEGJ-UHFFFAOYSA-N 0.000 claims 1
- UTGYYSGHKXUZKG-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[1-(2-methoxyethyl)piperidin-4-yl]benzamide Chemical compound C1CN(CCOC)CCC1C1=CC=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=C1 UTGYYSGHKXUZKG-UHFFFAOYSA-N 0.000 claims 1
- CCFZQBPNVWLORY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[4-(1-hydroxypropan-2-yl)piperazin-1-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)C(C)CO)=C2)=C1 CCFZQBPNVWLORY-UHFFFAOYSA-N 0.000 claims 1
- MJPBGKOMAIKXKT-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[4-(2-hydroxyethyl)piperazin-1-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCN(CCO)CC3)C=2)=C1 MJPBGKOMAIKXKT-UHFFFAOYSA-N 0.000 claims 1
- YRUSWYQIJJOVDF-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-[[methyl(oxolan-2-ylmethyl)amino]methyl]benzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(CN(C)CC4OCCC4)=CC=3)C=2)=C1 YRUSWYQIJJOVDF-UHFFFAOYSA-N 0.000 claims 1
- UWEOHTNKAYJXLK-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-fluorobenzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(F)=CC=3)=C2)=C1 UWEOHTNKAYJXLK-UHFFFAOYSA-N 0.000 claims 1
- XCNZLIDTXJNYHX-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-iodobenzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(I)=CC=3)=C2)=C1 XCNZLIDTXJNYHX-UHFFFAOYSA-N 0.000 claims 1
- PWQTURYNFGJDOR-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC(CCC=2C=C(OC)C=C(OC)C=2)=NN1 PWQTURYNFGJDOR-UHFFFAOYSA-N 0.000 claims 1
- PUTWNWIKRNTSFT-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-morpholin-4-ylbenzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCOCC3)=C2)=C1 PUTWNWIKRNTSFT-UHFFFAOYSA-N 0.000 claims 1
- LENFIJCVVDHYLK-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-piperazin-1-ylbenzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCNCC3)C=2)=C1 LENFIJCVVDHYLK-UHFFFAOYSA-N 0.000 claims 1
- JPKARPBPMGZAJP-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-piperidin-1-ylbenzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCCCC3)C=2)=C1 JPKARPBPMGZAJP-UHFFFAOYSA-N 0.000 claims 1
- GHALDBAFXAVMMP-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-piperidin-4-ylbenzamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)C3CCNCC3)C=2)=C1 GHALDBAFXAVMMP-UHFFFAOYSA-N 0.000 claims 1
- SAXJUWBPYDYASN-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)C=3CCN(C)CC=3)=C2)=C1 SAXJUWBPYDYASN-UHFFFAOYSA-N 0.000 claims 1
- ZIPLHWXKFUXUNN-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(1-methylpiperidin-4-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)C3CCN(C)CC3)=C2)=C1 ZIPLHWXKFUXUNN-UHFFFAOYSA-N 0.000 claims 1
- QFFQLQYWNFGCKQ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(3,3-dimethylpiperazin-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC(C)(C)NCC3)=C2)=C1 QFFQLQYWNFGCKQ-UHFFFAOYSA-N 0.000 claims 1
- JFUSILMVWGCWLX-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(3,4-dimethylpiperazin-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC(C)N(C)CC3)=C2)=C1 JFUSILMVWGCWLX-UHFFFAOYSA-N 0.000 claims 1
- ZNGRBVZIZAFWNU-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(4-ethyl-1,4-diazepan-1-yl)pyrazine-2-carboxamide Chemical compound C1CN(CC)CCCN1C1=CN=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=N1 ZNGRBVZIZAFWNU-UHFFFAOYSA-N 0.000 claims 1
- IYRCAAUUYKMAKQ-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(4-methyl-1,4-diazepan-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(C)CCC3)=C2)=C1 IYRCAAUUYKMAKQ-UHFFFAOYSA-N 0.000 claims 1
- OVNWQCURJHAVGY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(4-methylpiperazin-1-yl)thiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3SC(=CC=3)N3CCN(C)CC3)=C2)=C1 OVNWQCURJHAVGY-UHFFFAOYSA-N 0.000 claims 1
- GMKZWTWCMBSCGK-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(4-prop-2-enyl-1,4-diazepan-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(CC=C)CCC3)=C2)=C1 GMKZWTWCMBSCGK-UHFFFAOYSA-N 0.000 claims 1
- LUHURQHAFYBLBY-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(4-propan-2-yl-1,4-diazepan-1-yl)pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CCN(CCC3)C(C)C)=C2)=C1 LUHURQHAFYBLBY-UHFFFAOYSA-N 0.000 claims 1
- OCWXAVNWIGGMBR-CALCHBBNSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-[(3r,5s)-3,4,5-trimethylpiperazin-1-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3C[C@@H](C)N(C)[C@@H](C)C3)=C2)=C1 OCWXAVNWIGGMBR-CALCHBBNSA-N 0.000 claims 1
- WNKZQUJCJALKIX-IYBDPMFKSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-[(3r,5s)-3,5-dimethylpiperazin-1-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3C[C@@H](C)N[C@@H](C)C3)=C2)=C1 WNKZQUJCJALKIX-IYBDPMFKSA-N 0.000 claims 1
- CDLCIPZEXTYNPH-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-[3-(dimethylamino)pyrrolidin-1-yl]pyrazine-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3N=CC(=NC=3)N3CC(CC3)N(C)C)=C2)=C1 CDLCIPZEXTYNPH-UHFFFAOYSA-N 0.000 claims 1
- NCZOJGDOHRHOQD-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-[3-(methylamino)pyrrolidin-1-yl]pyrazine-2-carboxamide Chemical compound C1C(NC)CCN1C1=CN=C(C(=O)NC=2NN=C(CCC=3C=C(OC)C=C(OC)C=3)C=2)C=N1 NCZOJGDOHRHOQD-UHFFFAOYSA-N 0.000 claims 1
- XVRPCVLXVGHVAA-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-piperazin-1-ylthiophene-2-carboxamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3SC(=CC=3)N3CCNCC3)C=2)=C1 XVRPCVLXVGHVAA-UHFFFAOYSA-N 0.000 claims 1
- UCUOXLSNCCLZBK-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-piperazin-1-ylpyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=NC(=CC=3)N3CCNCC3)C=2)=C1 UCUOXLSNCCLZBK-UHFFFAOYSA-N 0.000 claims 1
- YVHYCABINBWMSD-UHFFFAOYSA-N n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]benzamide Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3C=CC=CC=3)=C2)=C1 YVHYCABINBWMSD-UHFFFAOYSA-N 0.000 claims 1
- NERSYEVEMXIENO-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(1,2,4-triazol-1-yl)benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3N=CN=C3)=C2)=C1 NERSYEVEMXIENO-UHFFFAOYSA-N 0.000 claims 1
- MXFBGPIFXVDVTK-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(1,3-oxazol-5-yl)benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)C=3OC=NC=3)=C2)=C1 MXFBGPIFXVDVTK-UHFFFAOYSA-N 0.000 claims 1
- LOVODCJIKKDXSM-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 LOVODCJIKKDXSM-UHFFFAOYSA-N 0.000 claims 1
- JNHJFIWNWXVPHO-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylsulfonylpiperazin-1-yl)benzamide Chemical compound COC1=CC=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3CCN(CC3)S(C)(=O)=O)C=2)=C1 JNHJFIWNWXVPHO-UHFFFAOYSA-N 0.000 claims 1
- WCGDVAQMLCCSHF-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(tetrazol-1-yl)benzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3N=NN=C3)=C2)=C1 WCGDVAQMLCCSHF-UHFFFAOYSA-N 0.000 claims 1
- QXIBHSZJCFGLSW-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-methylsulfonylbenzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)S(C)(=O)=O)=C2)=C1 QXIBHSZJCFGLSW-UHFFFAOYSA-N 0.000 claims 1
- IPDAVNIQTDGVHJ-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-oxo-1h-pyridine-2-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3N=CC=C(O)C=3)=C2)=C1 IPDAVNIQTDGVHJ-UHFFFAOYSA-N 0.000 claims 1
- DWNMLVLUEUYNEV-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-pyrazol-1-ylbenzamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3N=CC=C3)=C2)=C1 DWNMLVLUEUYNEV-UHFFFAOYSA-N 0.000 claims 1
- MKWKYJBXOMZCGN-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-(prop-2-ynylamino)pyridine-2-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3N=CC(NCC#C)=CC=3)=C2)=C1 MKWKYJBXOMZCGN-UHFFFAOYSA-N 0.000 claims 1
- HHHMAWQHXWYEMS-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-5-methylpyrazine-2-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3N=CC(C)=NC=3)=C2)=C1 HHHMAWQHXWYEMS-UHFFFAOYSA-N 0.000 claims 1
- RYIUGXUIDYOLFJ-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-(2-pyrrolidin-1-ylethyl)pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(CCN4CCCC4)=CC=3)=C2)=C1 RYIUGXUIDYOLFJ-UHFFFAOYSA-N 0.000 claims 1
- BUYXVORXGIUHMH-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-methylpyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(C)=CC=3)=C2)=C1 BUYXVORXGIUHMH-UHFFFAOYSA-N 0.000 claims 1
- IHCHQEBYCOBAGV-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(=CC=3)N3CCOCC3)=C2)=C1 IHCHQEBYCOBAGV-UHFFFAOYSA-N 0.000 claims 1
- KCSJEJZNVGZZHO-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-oxo-1h-pyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(O)=CC=3)=C2)=C1 KCSJEJZNVGZZHO-UHFFFAOYSA-N 0.000 claims 1
- BZWUWVKEJZYNEK-UHFFFAOYSA-N n-[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]-6-pyrazol-1-ylpyridine-3-carboxamide Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(=CC=3)N3N=CC=C3)=C2)=C1 BZWUWVKEJZYNEK-UHFFFAOYSA-N 0.000 claims 1
- KDBSSIATPVEZQM-UHFFFAOYSA-N n-[5-[2-(furan-2-yl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC=3OC=CC=3)C=2)C=C1 KDBSSIATPVEZQM-UHFFFAOYSA-N 0.000 claims 1
- BOADZWPFOWQIRX-UHFFFAOYSA-N n-[5-[2-(furan-3-yl)ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2NN=C(CCC3=COC=C3)C=2)C=C1 BOADZWPFOWQIRX-UHFFFAOYSA-N 0.000 claims 1
- IQNLCUHYNOFIIG-UHFFFAOYSA-N n-[5-[2-[3-(2-methoxyethoxy)phenyl]ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound COCCOC1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 IQNLCUHYNOFIIG-UHFFFAOYSA-N 0.000 claims 1
- IKCJWUFUEGARTD-UHFFFAOYSA-N n-[5-[2-[5-[(dimethylamino)methyl]furan-2-yl]ethyl]-1h-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound O1C(CN(C)C)=CC=C1CCC1=CC(NC(=O)C=2C=CC(=CC=2)N2CCN(C)CC2)=NN1 IKCJWUFUEGARTD-UHFFFAOYSA-N 0.000 claims 1
- DRBFMRQQSOQEMH-UHFFFAOYSA-N n-methyl-3-[2-[3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-1h-pyrazol-5-yl]ethyl]benzamide Chemical compound CNC(=O)C1=CC=CC(CCC2=NNC(NC(=O)C=3C=CC(=CC=3)N3CCN(C)CC3)=C2)=C1 DRBFMRQQSOQEMH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- GFSSREOCZPVSRP-UHFFFAOYSA-N prop-2-enyl n-[5-[[5-[2-(3-methoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]pyridin-2-yl]carbamate Chemical compound COC1=CC=CC(CCC2=NNC(NC(=O)C=3C=NC(NC(=O)OCC=C)=CC=3)=C2)=C1 GFSSREOCZPVSRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 claims 1
- KWVGLKZINKFZDB-UHFFFAOYSA-N tert-butyl 4-[5-[[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]carbamoyl]thiophen-2-yl]piperazine-1-carboxylate Chemical compound COC1=CC(OC)=CC(CCC2=NNC(NC(=O)C=3SC(=CC=3)N3CCN(CC3)C(=O)OC(C)(C)C)=C2)=C1 KWVGLKZINKFZDB-UHFFFAOYSA-N 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Spoj formule (I): ili njegova farmaceutski prihvatljiva solnaznačen time da prsten A predstavlja 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora; prsten B predstavlja 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora; R1 svaki nezavisno predstavljajuhalogen, hidroksilnu skupinu, cijano skupinu, C1-C3alkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR4R5 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, C3-5cikloalkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR6R7 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, C2-C3alkenilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR8R9 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, fenilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR10R11 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, 4- do 6-članu heterocikličku skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR12R13 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, C1-C3alkoksi skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, -NR14R15, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, -NR16R17 skupinu, -OCOR18 skupinu, -CO2R19 skupi
Claims (18)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol
naznačen time da
prsten A predstavlja 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora;
prsten B predstavlja 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora;
R1 svaki nezavisno predstavljaju
halogen,
hidroksilnu skupinu,
cijano skupinu,
C1-C3alkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR4R5 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
C3-5cikloalkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR6R7 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
C2-C3alkenilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR8R9 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
fenilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR10R11 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
4- do 6-članu heterocikličku skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR12R13 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
C1-C3alkoksi skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, -NR14R15, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
-NR16R17 skupinu,
-OCOR18 skupinu,
-CO2R19 skupinu,
-CONR20R21 skupinu,
-NR22COR23 skupinu,
-NR24CO2R25 skupinu,
-OSO2R26 skupinu,
ili dvije susjedne R1 skupine zajedno sa atomima na koje su spojene tvore 4- do 7-člani karbociklički ili heterociklički prsten koji je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR27R28 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila;
R2 svaki nezavisno predstavljaju
hidroksilnu skupinu,
halogen,
cijano skupinu,
-CO2R29 skupinu,
-CONR30R31 skupinu,
-NR32COR33 skupinu,
-NR34CO2R35 skupinu,
-NR36R37 skupinu,
-SO2R38 skupinu,
-SO2NR39R40 skupinu,
-NR41SO2R42 skupinu,
C1-C6alkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR43R44, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, C3-C6cikloalkila, amino (-NH2), mono- i di-C1-C3alkilamino, cijano, hidroksil trifluorometila i 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, C3-C6cikloalkila, amino (-NH2), mono- i di-C1-C3alkilamino, cijano, hidroksila, trifluorometila), halogena, hidroksila, te 4- do 7-člane heterocikličke skupine koja je proizvoljno kondenzirana na 4- do 7-članu karbocikličku ili heterocikličku skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR45R46, -CO2R47 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), cijano, halogena i hidroksila,
C3-C6cikloalkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR48R49 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena, hidroksila, te 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR50R51 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
C2-C6alkenilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR52R53, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena, hidroksila, te 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, NR54R55 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
4- do 7-članu heterocikličku skupinu koja je proizvoljno kondenzirana na 4- do 7-članu karbocikličku ili heterocikličku skupinu i proizvoljno je supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C2-C6alkenila, C2-C6alkinila, C1-C6alkoksi, C1-C6alkilkarbonila, C3-C6cikloalkila, C1-C6alkiltio, -NR56R57, SO2R58 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, cijano, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena, okso, hidroksila i 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR59R60, -SO2R61 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
C1-C6alkoksi skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkoksi, C3-C6cikloalkila, -NR62R63 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena, hidroksila i 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C6alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C6alkiltio, -NR64R65 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila,
ili dvije susjedne R2 skupine zajedno sa atomima na koje su spojeni tvore 4- do 7-člani karbociklički ili heterociklički prsten koji je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR66R67 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila;
R3 predstavlja vodik,
C1-C3alkilnu skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, C1-C3alkiltio, -NR68R69 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila;
a je 0, 1, 2, 3 ili 4;
b je 0, 1, 2, 3 ili 4;
R4 i R5 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R4 i R5 zajedno sa atomom dušika na kojeg su vezani tvore 4- do 6-člani zasićeni heterocikal;
R6 i R7 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R6 i R7 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R8 i R9 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R8 i R9 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R10 i R11 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R10 i R11 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R12 i R13 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R12 i R13 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R14 i R15 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R14 i R15 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R16 i R17 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R16 i R17 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R18 predstavlja C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R19 predstavlja vodik, C1-C4alkil, C2-C4alkenil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R20 i R21 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R20 i R21 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R22 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R23 predstavlja C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R24 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R25 predstavlja C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R26 predstavlja C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R27 i R28 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R27 i R28 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R29 predstavlja vodik, C1-C4alkil, C2-C4alkenil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R30 i R31 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R30 i R31 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R32 predstavlja vodik, C1-C4alkil, C2-C4alkenil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R33 predstavlja vodik, C1-C4alkil, C3-C6cikloalkil ili 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R34 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R35 predstavlja vodik, C1-C4alkil, C2-C4alkenil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R36 i R37 svaki nezavisno predstavljaju vodik, C1-C4alkil, C2-C4alkinil, C3-C6cikloalkil ili 5- ili 6-članu aromatsku skupinu koja proizvoljno sadrži barem jedan heteroatom u prstenu koji je odabran od dušika, kisika i sumpora, ili R36 i R37 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila, trifluorometila i 4- do 7-člane karbocikličke ili heterocikličke skupine koja proizvoljno može biti supstituirana sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila, trifluorometila);
R38 predstavlja C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R39 i R40 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R39 i R40 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R41 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R42 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, C1-C3alkiltio, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila);
R43 i R44 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R43 i R44 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R45 i R46 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R45 i R46 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R47 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil;
R48 i R49 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R48 i R49 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R50 i R51 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R50 i R51 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R52 i R53 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R52 i R53 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R54 i R55 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R54 i R55 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R56 i R57 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R56 i R57 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R58 predstavlja C1-C4alkil ili C3-C6cikloalkil;
R59 i R60 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R59 i R60 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R61 predstavlja C1-C4alkil ili C3-C6cikloalkil;
R62 i R63 svaki nezavisno predstavljaju vodik, C1-C4alkil ili C3-C6cikloalkil, ili R62 i R63 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R64 i R65 svaki nezavisno predstavljaju vodik, C1-C6alkil ili C3-C6cikloalkil, ili R64 i R65 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R66 i R67 svaki nezavisno predstavljaju vodik, C1-C6alkil ili C3-C6cikloalkil, ili R66 i R67 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal;
R68 i R69 svaki nezavisno predstavljaju vodik, C1-C6alkil ili C3-C6cikloalkil, ili R68 i R69 zajedno sa atomom dušika na kojeg su spojeni tvore 4- do 6-člani zasićeni heterocikal; te gdje
kada Y predstavlja CH2, X predstavlja CH2, O, NR70 ili S(O)x pri čemu R70 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil, te x je 0, 1 ili 2; ili
kada X predstavlja CH2, Y predstavlja CH2, O, NR71 ili S(O)y pri čemu R71 predstavlja vodik, C1-C4alkil ili C3-C6cikloalkil, te y je 0, 1 ili 2.
2. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da R3 je vodik.
3. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1 ili 2, naznačen time, da X predstavlja CH2 ili O; te Y predstavlja CH2.
4. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva od 1 do 3, naznačen time, da svaki R2 nezavisno predstavlja -Cl; -F; -I; -OH; -CN; -CH3; -CH2OH; -CH2N(CH3)2; -CH2CH(CH3)NH2; -OCH3; -OCH2CH2OH; -OCH2CH2OCH2CH3; -SO2CH3; -N(CH3)2; -NHPh; -NHCH2C≡CH; -NHCH2CH3; -NHCH2CH2N(CH3)2; -NHCO2CH2CH=CH2; -NHCOCH3; -NHCOH; -NHCOPh; -CONH2; -NHSO2Me; -SO2N(CH3)2; -CO2H; -CO2CH3; -CO2CH2CH3;
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili
[image]
skupinu.
5. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 4, naznačen time, da svaki R1 nezavisno predstavlja C1-C3alkoksi skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, -NR14R15, (svaki od njih je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, ili -CONR20R21 skupinu.
6. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 5, naznačen time, da prsten A predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni, tenilni ili tiazolilni prsten.
7. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 6, naznačen time, da prsten B predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni, tenilni ili tiazolilni prsten.
8. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da:
prsten A predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni, tenilni ili tiazolilni prsten;
prsten B predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni, tenilni ili tiazolilni prsten;
svaki R1 nezavisno predstavlja C1-C3alkoksi skupinu koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkoksi, C3-cikloalkila, -NR14R15, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C3alkila, C1-C3alkoksi, amino (-NH2), mono- i di-C1-C3alkilamino, hidroksila i trifluorometila), halogena i hidroksila, ili -CONR20R21 skupinu;
R2 predstavlja
[image]
pri čemu
G1 je C ili N,
n je 1 ili 2,
RC1, RC2 , RC3 i RC4 su svaki nezavisno odabrani od C1-C3alkila, C2-C3alkenila, C2-C3alkinila, C3-C5cikloalkila, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila), vodika, halogena i hidroksila, ili
RC1 i RC2 i/ili RC3 i RC4 zajedno sa atomom na kojeg su spojeni tvore 3- do 6-člani karbociklički ili heterociklički prsten koji je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila, ili
RC1 i RC3 zajedno sa atomima na koje su spojeni i sa atomom dušika na kojeg je spojena RN1 skupina tvore 5- do 7-člani karbociklički ili heterociklički prsten koji je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila, a RN1 je odabran od C1-C4alkila, C2-C4alkenila, C2-C4alkinila, C3-C6cikloalkila, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od cijano, halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila), vodika i 4- do 7-člane heterocikličke skupine koja je proizvoljno supstituirana sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C1-C3alkoksi, C3-C5cikloalkila, C1-C3alkiltio, -NR59R60, -SO2R61 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila), halogena i hidroksila, ili
RN1 i RC4 zajedno sa atomima na koje su spojeni tvore 4- do 7-člani heterociklički prsten koji je proizvoljno supstituiran sa jednim ili više supstituenata koji su odabrani od C1-C3alkila, C2-C3alkenila, C2-C3alkinila, C1-C3alkoksi, C3-C5cikloalkila, C1-C3alkiltio, -NR56R57, SO2R58 (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila), halogena, hidroksila;
R3 predstavlja vodik;
X predstavlja CH2 ili O;
Y predstavlja CH2;
a je 0, 1 ili 2; te
b je 1.
9. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da:
prsten A predstavlja fenilni prsten;
prsten B predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni ili tenilni prsten;
svaki R1 nezavisno predstavlja C1-C3alkoksi skupinu;
R2 predstavlja
[image]
pri čemu
G1 je C ili N,
n je 1 ili 2,
RC1, RC2 RC3 i RC4 su svaki nezavisno odabrani od vodika, metila, etila, hidroksimetila, hidroksietila, metoksimetila, metoksietila, 2,2,2-trifluoroetila, ili
RC3 i RC4 zajedno sa atomom na kojeg su spojeni tvore 3- do 5-člani karbociklički prsten, te
RN1 je odabran od C1-C2alkila, C2-C3alkenila, C2-C3alkinila, C3-C5cikloalkila, (svaki od njih može proizvoljno biti supstituiran sa jednim ili više supstituenata koji su odabrani od halogena, C1-C2alkila, C1-C2alkoksi, C1-C2alkiltio, amino (-NH2), mono- i di-C1-C2alkilamino, hidroksila i trifluorometila) i vodika, ili
RN1 i RC4 zajedno sa atomima na koje su spojeni tvore 4- do 7-člani heterociklički prsten;
R3 predstavlja vodik;
X predstavlja CH2 ili O;
Y predstavlja CH2;
a je 0, 1 ili 2; te
b je 1.
10. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da:
A(R1)a predstavlja 3,5-dimetoksifenil;
prsten B predstavlja fenilni, pirazinilni, pirimidinilni ili tenilni prsten;
R2 predstavlja
[image]
pri čemu
G1 je C ili N,
n je 1,
RC1, RC2 RC3 i RC4 su svaki nezavisno odabrani od vodika, metila, etila, hidroksimetila, hidroksietila, metoksimetila, metoksietila, 2,2,2-trifluoroetila, ili
RC3 i RC4 zajedno sa atomom na kojeg spojeni tvore ciklopropilni prsten, te
RN1 je odabran od vodika, metila, etila, metoksietila, etoksietila, hidroksietila, propenila, propinila, i-propila, -CH(CH3)CH2OH, ciklopropila, ciklobutila, ciklopentila, ili
RN1 i RC4 zajedno sa atomima na koje su spojeni tvore 5- ili 6-člani heterociklički prsten;
R3 predstavlja vodik;
X predstavlja CH2 ili O;
Y predstavlja CH2; te
b je 1.
11. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva od 1 do 3, naznačen time, da:
-A-(R1)a predstavlja
[image]
skupinu; te
-B-(R2)b predstavlja
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
skupinu.
12. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 3, naznačen time, da:
-A-(R1)a predstavlja
[image]
skupinu; te
-B-(R2)b predstavlja
[image]
[image]
[image]
[image]
[image]
[image]
[image]
skupinu.
13. Spoj formule (I) prema zahtjevu 1, naznačen time, da je navedeni spoj odabran od
4-(4-metilpiperazin-1-il)-N-(5-fenetil-2H-pirazol-3-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-metoksi-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-morfolin-4-il-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[(3-fluoro-1-piperidil)metil]benzamida,
N-[5-[2-[3-(2-Metoksietoksi)fenil]etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
4-(4-Metilpiperazin-1-il)-N-[5-(2-piridin-3-iletil)-2H-pirazol-3-il]benzamida,
N-[5-[2-(2-furil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(3-furil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(3-Metoksifenil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[(3,5-Dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(3-Metoksifenil)etil]-2H-pirazol-3-il]-6-metil-piridin-3-karboksamida,
6-Metoksi-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
N-[5-[2-(3-Metoksifenil)etil]-2H-pirazol-3-il]-4-metilsulfonil-benzamida,
N-[5-[2-(3-Metoksifenil)etil]-2H-pirazol-3-il]-5-metil-pirazin-2-karboksamida,
N-[5-[2-(3-Metoksifenil)etil]-2H-pirazol-3-il]-5-(prop-2-inilamino)piridin-2-karboksamida,
6-Etilamino-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
4-Acetamido-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[(3,5-Dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(4-metilpiperazin-1-il)pirazin-2-karboksamida,
4-benzamido-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
6-(2-metoksietoksi)-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
4-cijano-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzen-1,4-dikarboksamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-4-pirazol-1-il-benzamida,
6-anilino-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
4-metansulfonamido-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
4-(hidroksimetil)-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
5-formamido-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-2-karboksamida,
4-(dimetilsulfamulja)-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]benzamida,
6-hidroksi-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-6-morfolin-4-il-piridin-3-karboksamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-4-(1,3-oksazol-5-il)benzamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-4-(tetrazol-1-il)benzamida,
prop-2-enil N-[5-[[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]karbamoil]piridin-2-il]karbamata,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-4-(1,2,4-triazol-1-il)benzamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-6-pirazol-1-il-piridin-3-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-fluoro-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-3-metoksi-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-3-morfolin-4-il-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-2-metoksi-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(2-etoksietoksi)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(1-piperidil)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(4-piperidilmetoksi)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-piperazin-1-il-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-6-piperazin-1-il-piridin-3-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(dimetilaminometil)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(2-hidroksietoksi)benzamida,
4-(2-aminopropil)-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-[(3,3-dimetil-1-piperidil)metil]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-[4-(2-hidroksietil)piperazin-1-il]benzamida,
4-[(7-cijano-3,4-dihidro-1H-izokinolin-2-il)metil]-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-[(3-fluoro-1-piperidil)metil]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(2-morfolin-4-iletoksi)benzamida,
4-[2-(4,4-difluoro-1-piperidil)etoksi]-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(2-morfolin-4-iletil)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-[(metil-(oksolan-2-ilmetil)amino)metil]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(4-piperidil)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-dimetilamino-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-5-piperazin-1-il-tiofen-2-karboksamida,
metil 6-[[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]karbamoil]piridin-3-karboksilata,
6-kloro-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
6-cijano-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-3-karboksamida,
4-hidroksi-N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]piridin-2-karboksamida,
N-[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]-6-(2-pirolidin-1-iletil)piridin-3-karboksamida,
5-[[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]karbamoil]piridin-2-karboksilne kiseline,
metil 5-[[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]karbamoil]piridin-2-karboksilata,
etil 5-[[5-[2-(3-metoksifenil)etil]-2H-pirazol-3-il]karbamoil]piridin-2-karboksilata,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(4-metilpiperazin-1-il)piridin-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(2-dimetilaminoetilamino)benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-metoksi-benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-6-piperazin-1-il-piridin-3-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-1H-pirazol-3-il]-2-(4-metilpiperazin-1-il)pirimidin-5-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-1H-pirazol-3-il]-3-piperazin-1-il-benzamida,
4-(1,4-diazepan-1-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-1H-pirazol-3-il]benzamida,
N-[5-[2-[5-(dimetilaminometil)-2-furil]etil]-1H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-(2-benzo[1,3]dioksol-5-iletil)-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(2,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(4-metoksi-2-metil-fenil)etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(3,5-dimetilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-jodo-benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-2-[(3-metil-1,2-oksazol-5-il)metilamino]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-6-(4-metilpiperazin-1-il)piridazin-3-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-metilpiperazin-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(4-metilpiperazin-1-karbonil)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(4-propan-2-ilpiperazin-1-il)benzamida,
4-(4-ciklopropilpiperazin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
4-(4-ciklobutilpiperazin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
4-(4-acetilpiperazin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]benzamida,
N-[5-[2-(3-metoksifenil)etil]-1H-pirazol-3-il]-4-(4-metilsulfonilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(1-metil-4-piperidil)benzamida,
4-(3,4,6,7,8,8a-Heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
4-(1,3,4,6,7,8,9,9a-Oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-[(4-metilpiperazin-1-il)metil]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(3,4-dimetilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(3,4,5-trimetilpiperazin-1-il)benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(3,4-dimetilpiperazin-1-il)tiofen-2-karboksamida,
4-(1,3,4,6,7,8,9,9a-oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]benzamida,
4-(1-Ciklopropilpiperidin-4-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-[(3R,5S)-3,5-dimetilpiperazin-1-il]benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(3,4-dimetilpiperazin-1-il)benzamida,
tert-Butil 4-[5-[[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]karbamoil]tiofen-2-il]piperazin-1-karboksilata,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(1-metilpiperidin-4-il)benzamida,
4-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]benzamida,
5-(1,3,4,6,7,8,9,9a-Oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-metilpiperazin-1-il)tiofen-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(4-metilpiperazin-1-il)tiofen-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(3,3-dimetilpiperazin-1-il)pirazin-2-karboksamida,
5-(4-Ciklopropilpiperazin-1-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-[(3R,5S)-3,4,5-trimetilpiperazin-1-il]benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(3,3-dimetilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-[(3R,5S)-3,5-dimetilpiperazin-1-il]pirazin-2-karboksamida,
5-(4-Ciklopropilpiperazin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3- il]pirazin-2-karboksamida,
5-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirazin-2-karboksamida,
5-(1,3,4,6,7,8,9,9a-Oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirazin-2-karboksamida,
4-(4-ciklopropilpiperazin-1-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-Dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-metil-4-oksidopiperazin-4-ij-1-il)benzamida,
4-(4-Ciklobutilpiperazin-1-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]benzamida,
2-(1,3,4,6,7,8,9,9a-Oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirimidin-5-karboksamida,
5-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]tiofen-2-karboksamida,
5-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]tiofen-2-karboksamida,
5-(3,4,6,7,8,8a-Heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[2-(3,5-Dimetoksifenil)etil]-2H-pirazol-3-il]-5-(3,4-dimetilpiperazin-1-il)pirazin-2-karboksamida,
N-[5-[(3,5-Dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(3,4-dimetilpiperazin-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-[(3R,5S)-3,4,5-trimetilpiperazin-1-il]pirazin-2-karboksamida,
2-(4-ciklopropilpiperazin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirimidin-5-karboksamida,
2-(1,3,4,6,7,8,9,9a-oktahidropirido[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirimidin-5-karboksamida,
2-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirimidin-5-karboksamida,
5-[(3R,5S)-4-(cijanometil)-3,5-dimetilpiperazin-1-il]-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-[(3R,5S)-3,4,5-trimetilpiperazin-1-il]pirazin-2-karboksamida,
5-[(3R,5S)-4-(cijanometil)-3,5-dimetilpiperazin-1-il]-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-2-(3,4-dimetilpiperazin-1-il)pirimidin-5-karboksamida,
2-(4-ciklopropilpiperazin-1-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirimidin-5-karboksamida,
2-(3,4,6,7,8,8a-heksahidro-1H-pirolo[2,1-c]pirazin-2-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(3,4-dimetilpiperazin-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-[(3R,5S)-3,4,5-trimetilpiperazin-1-il]pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[4-(1-hidroksipropan-2-il)piperazin-1-il]benzamida,
N-(3-(3,5-dimetoksibenziloksi)-1H-pirazol-5-il)-2-((3R,5S)-3,4,5-trimetilpiperazin-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(3,3-dimetilpiperazin-1-il)benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(3,3-dimetilpiperazin-1-il)tiofen-2-karboksamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-(4-etilpiperazin-1-il)tiofen-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-metil-1,4-diazepan-1-il)tiofen-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-etil-3-metilpiperazin-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(1-prop-2-enilpiperidin-4-il)benzamida,
4-(1,4-diazepan-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(1-prop-2-inilpiperidin-4-il)benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-5-[(3S,5R)-3,5-dimetilpiperazin-1-il]tiofen-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[1-(2-metoksietil)piperidin-4-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-[(3S)-3-propan-2-ilpiperazin-1-il]pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-metil-3-oksopiperazin-1-il)pirimidin-5-karboksamida,
4-(1,2,3,4,4a,5,7,7a-oktahidropirolo[3,4-b]piridin-6-il)-N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(1-metilpiperidin-4-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(1-metil-3,6-dihidro-2H-piridin-4-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[(3R,5S)-3,5-dimetilpiperazin-1-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[(3R,5S)-3,4,5-trimetilpiperazin-1-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-metil-1,4-diazepan-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(3-dimetilaminopirolidin-1-il)pirazin-2-karboksamida,
5-(3-dietilaminopirolidin-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(1-etilpiperidin-4-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-[3-(metoksimetil)piperazin-1-il]pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(3-metilaminopirolidin-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(1-metilpiperidin-4-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-metil-1,4-diazepan-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-prop-2-enil-1,4-diazepan-1-il)benzamida,
4-(4-ciklopropil-1,4-diazepan-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-propan-2-il-1,4-diazepan-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-propan-2-il-1,4-diazepan-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-propan-2-il-1,4-diazepan-1-il)tiofen-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-etil-1,4-diazepan-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-etil-1,4-diazepan-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-etil-1,4-diazepan-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-5-(4-prop-2-enil-1,4-diazepan-1-il)pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-propan-2-il-1,4-diazepan-1-il)pirimidin-5-karboksamida,
5-(4-ciklopropil-1,4-diazepan-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirazin-2-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-prop-2-enil-1,4-diazepan-1-il)pirimidin-5-karboksamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-2-(4-metil-1,4-diazepan-1-il)pirimidin-5-karboksamida,
2-(4-ciklopropil-1,4-diazepan-1-il)-N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]pirimidin-5-karboksamida,
N-[5-[2-[3-(metilkarbamoil)fenil]etil]-2H-pirazol-3-il]-4-(4-metilpiperazin-1-il)benzamida,
N-[5-[(3,5-dimetoksifenil)metoksi]-2H-pirazol-3-il]-4-(4-etilpiperazin-1-il)benzamida,
N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-(4-etilpiperazin-1-il)benzamida
i njihove farmaceutski prihvatljive soli.
14. Spoj formule (I) prema zahtjevu 1, naznačen time, da navedeni spoj je N-[5-[2-(3,5-dimetoksifenil)etil]-2H-pirazol-3-il]-4-[(3R,5S)-3,5-dimetilpiperazin-1-il]benzamid.
15. Spoj formule (I) prema zahtjevu 1, naznačen time, da navedeni spoj je N-[5-[2-(3,5-dimetoksifenil)etil]-1H-pirazol-3-il]-4-(3,4-dimetilpiperazin-1-il)benzamid.
16. Upotreba spoja formule (I) ili njegove farmaceutski prihvatljive soli, prema bilo kojem od zahtjeva 1 do 15, naznačena time, da je za proizvodnju lijeka koji se upotrebljava kod liječenja.
17. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se upotrebljava kao lijek.
18. Farmaceutski pripravak koji sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do 15, naznačen time, da dodatno sadrži farmaceutski prihvatljivi dodatak, razrjeđivač ili nosač.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87119006P | 2006-12-21 | 2006-12-21 | |
US98554207P | 2007-11-05 | 2007-11-05 | |
PCT/GB2007/004917 WO2008075068A2 (en) | 2006-12-21 | 2007-12-20 | Acylaminopyrazoles as fgfr inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110520T1 true HRP20110520T1 (hr) | 2011-08-31 |
Family
ID=39536793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110520T HRP20110520T1 (hr) | 2006-12-21 | 2011-07-11 | Acilaminopirazoli kao inhibitori fgfr |
Country Status (29)
Country | Link |
---|---|
US (6) | US7737149B2 (hr) |
EP (1) | EP2125748B1 (hr) |
JP (1) | JP5000726B2 (hr) |
KR (1) | KR101467593B1 (hr) |
AR (1) | AR064454A1 (hr) |
AT (1) | ATE510825T1 (hr) |
AU (1) | AU2007336011B2 (hr) |
BR (1) | BRPI0720551A2 (hr) |
CA (1) | CA2672521C (hr) |
CO (1) | CO6210721A2 (hr) |
CY (1) | CY1111721T1 (hr) |
DK (1) | DK2125748T3 (hr) |
EC (1) | ECSP099436A (hr) |
HK (1) | HK1139137A1 (hr) |
HR (1) | HRP20110520T1 (hr) |
IL (1) | IL199019A (hr) |
MX (1) | MX2009006742A (hr) |
MY (1) | MY146111A (hr) |
NO (1) | NO342176B1 (hr) |
NZ (1) | NZ577209A (hr) |
PE (1) | PE20081532A1 (hr) |
PL (1) | PL2125748T3 (hr) |
PT (1) | PT2125748E (hr) |
RU (1) | RU2458920C2 (hr) |
SA (1) | SA07280734B1 (hr) |
SI (1) | SI2125748T1 (hr) |
TW (1) | TWI434846B (hr) |
UY (1) | UY30819A1 (hr) |
WO (1) | WO2008075068A2 (hr) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
PL2195293T3 (pl) | 2007-08-22 | 2014-03-31 | Astrazeneca Ab | Pochodne cyklopropyloamidu |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
JP2011524888A (ja) * | 2008-06-19 | 2011-09-08 | アストラゼネカ アクチボラグ | ピラゾール化合物436 |
MX2011006682A (es) | 2008-12-22 | 2011-07-13 | Merck Patent Gmbh | Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion. |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
NZ602110A (en) | 2010-02-18 | 2014-09-26 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
JP5343177B1 (ja) | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
WO2013133351A1 (ja) | 2012-03-08 | 2013-09-12 | アステラス製薬株式会社 | 新規fgfr3融合体 |
WO2013161871A1 (ja) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
WO2014002922A1 (ja) * | 2012-06-26 | 2014-01-03 | アステラス製薬株式会社 | 抗癌剤の併用による癌治療方法 |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
EP2964260A2 (en) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Methods of treating and preventing cancer drug resistance |
PL403149A1 (pl) * | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
AR096393A1 (es) * | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CN106660997B (zh) | 2014-08-18 | 2019-05-21 | 卫材R&D管理有限公司 | 单环吡啶衍生物的盐及其晶体 |
CN105524048B (zh) * | 2014-08-19 | 2019-11-12 | 上海海和药物研究开发有限公司 | 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016105517A1 (en) | 2014-12-23 | 2016-06-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
AU2016296205B2 (en) | 2015-07-17 | 2021-11-11 | Centre Hospitalier Sainte Anne Paris | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation |
WO2017028816A1 (zh) | 2015-08-20 | 2017-02-23 | 浙江海正药业股份有限公司 | 吲哚类衍生物及其制备方法和其在医药上的用途 |
CN107459519A (zh) * | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
AU2017295038B2 (en) | 2016-07-15 | 2022-09-22 | Centre Hospitalier Sainte Anne Paris | 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair |
CN107840842A (zh) | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MX2020008610A (es) | 2018-03-28 | 2020-09-21 | Eisai R&D Man Co Ltd | Agente terapeutico para carcinoma hepatocelular. |
JP2021523118A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Fgfr阻害剤の塩 |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤の誘導体 |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202237595A (zh) * | 2020-12-02 | 2022-10-01 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
US11957677B2 (en) | 2021-10-15 | 2024-04-16 | Cardiff Oncology, Inc. | Cancer treatment using FGFR inhibitors and PLK1 inhibitors |
WO2023180388A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
WO2024031226A1 (zh) * | 2022-08-08 | 2024-02-15 | 无锡和誉生物医药科技有限公司 | Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB843940A (en) | 1955-09-27 | 1960-08-10 | Kodak Ltd | Method of processing photographic silver halide emulsions containing colour couplers |
BE667399A (hr) | 1964-07-30 | 1965-11-16 | ||
JPS57150846A (en) | 1981-03-13 | 1982-09-17 | Konishiroku Photo Ind Co Ltd | Photographic element |
JPS63133152A (ja) | 1986-11-26 | 1988-06-04 | Konica Corp | 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料 |
JPH0467645A (ja) | 1990-07-09 | 1992-03-03 | Nec Kyushu Ltd | バーンイン装置 |
JP2890065B2 (ja) | 1990-11-10 | 1999-05-10 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
JPH04184437A (ja) | 1990-11-20 | 1992-07-01 | Fuji Photo Film Co Ltd | カラー画像形成方法及びハロゲン化銀カラー写真感光材料 |
JPH04292322A (ja) | 1991-03-19 | 1992-10-16 | Fujitsu Ltd | ラック給排装置 |
JPH0511414A (ja) | 1991-07-02 | 1993-01-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
BR9305466A (pt) | 1992-03-26 | 1994-12-20 | Dowelanco | Nitroanilinas n-heterocíclicas usadas como fungicidas |
HRP921338B1 (en) | 1992-10-02 | 2002-04-30 | Monsanto Co | Fungicides for the control of take-all disease of plants |
TW240217B (hr) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
JP3156026B2 (ja) | 1993-12-27 | 2001-04-16 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
CN1165482A (zh) | 1994-11-10 | 1997-11-19 | 科西雷佩蒂斯公司 | 用作蛋白激酶抑制剂的吡唑药物组合物 |
CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
WO1998052944A1 (en) | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
UA67763C2 (uk) * | 1997-12-22 | 2004-07-15 | Байер Фармасьютікалс Корпорейшн | Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf |
JP3310226B2 (ja) | 1998-10-16 | 2002-08-05 | 松下電器産業株式会社 | 音声合成方法および装置 |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
ATE286026T1 (de) | 1999-02-10 | 2005-01-15 | Mitsubishi Pharma Corp | Amid-derivate und deren medizinische verwendung |
WO2000049001A2 (en) | 1999-02-16 | 2000-08-24 | E.I. Du Pont De Nemours And Company | Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides |
ATE305782T1 (de) | 1999-08-12 | 2005-10-15 | Pharmacia Italia Spa | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel |
BR0013551A (pt) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
AU771460B2 (en) | 1999-09-24 | 2004-03-25 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
YU14703A (sh) * | 2000-08-31 | 2006-05-25 | Pfizer Products Inc. | Derivati pirazola i njihova upotreba kao inhibitora protein kinaze |
US20050209297A1 (en) | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
US20040043904A1 (en) | 2000-09-22 | 2004-03-04 | Hiroshi Yamaguchi | N-(4-pyrazolyl) amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
EP1352650B1 (en) | 2000-12-18 | 2012-03-07 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
JP2004538266A (ja) | 2001-04-27 | 2004-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール由来のキナーゼインヒビター |
EA008769B1 (ru) | 2002-06-05 | 2007-08-31 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения диабета |
EP1510210A4 (en) | 2002-06-05 | 2009-01-07 | Inst Med Molecular Design Inc | IMMUNITY-CONTAINING PROTEIN KINASE HEMMER |
EP1514544A4 (en) | 2002-06-06 | 2009-01-07 | Inst Med Molecular Design Inc | HYPO-ALLERGENIC |
ES2246603B1 (es) | 2002-07-03 | 2007-06-16 | Consejo Sup. De Investig. Cientificas | Procedimiento para la preparacion de esteres de hidroxitirosol, esteres obtenidos y utilizacion. |
AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
JP4171881B2 (ja) | 2002-08-09 | 2008-10-29 | 株式会社大塚製薬工場 | Acat−1阻害剤 |
DE602004028907D1 (de) | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
JP2004292322A (ja) | 2003-03-25 | 2004-10-21 | Fuji Photo Film Co Ltd | 水溶性アミド連結体の製造方法 |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
US7115359B2 (en) | 2003-07-25 | 2006-10-03 | Konica Minolta Medical & Graphic, Inc. | Photothermographic material |
AU2004268948A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
US7432271B2 (en) | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
US20050171172A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
US7671072B2 (en) | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
RU2008107868A (ru) | 2005-08-02 | 2009-09-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназ |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
-
2007
- 2007-12-18 US US11/958,720 patent/US7737149B2/en active Active
- 2007-12-19 AR ARP070105731A patent/AR064454A1/es not_active Application Discontinuation
- 2007-12-20 MY MYPI20092608A patent/MY146111A/en unknown
- 2007-12-20 KR KR1020097014263A patent/KR101467593B1/ko active IP Right Grant
- 2007-12-20 AU AU2007336011A patent/AU2007336011B2/en active Active
- 2007-12-20 AT AT07848646T patent/ATE510825T1/de active
- 2007-12-20 MX MX2009006742A patent/MX2009006742A/es active IP Right Grant
- 2007-12-20 TW TW096149024A patent/TWI434846B/zh active
- 2007-12-20 RU RU2009127644/04A patent/RU2458920C2/ru active
- 2007-12-20 EP EP07848646A patent/EP2125748B1/en active Active
- 2007-12-20 UY UY30819A patent/UY30819A1/es not_active Application Discontinuation
- 2007-12-20 SI SI200730655T patent/SI2125748T1/sl unknown
- 2007-12-20 CA CA2672521A patent/CA2672521C/en active Active
- 2007-12-20 NZ NZ577209A patent/NZ577209A/en not_active IP Right Cessation
- 2007-12-20 DK DK07848646.1T patent/DK2125748T3/da active
- 2007-12-20 WO PCT/GB2007/004917 patent/WO2008075068A2/en active Application Filing
- 2007-12-20 PL PL07848646T patent/PL2125748T3/pl unknown
- 2007-12-20 JP JP2009542220A patent/JP5000726B2/ja not_active Expired - Fee Related
- 2007-12-20 BR BRPI0720551-1A patent/BRPI0720551A2/pt not_active Application Discontinuation
- 2007-12-20 PT PT07848646T patent/PT2125748E/pt unknown
- 2007-12-29 SA SA07280734A patent/SA07280734B1/ar unknown
-
2008
- 2008-01-02 PE PE2008000012A patent/PE20081532A1/es active IP Right Grant
-
2009
- 2009-05-26 NO NO20092033A patent/NO342176B1/no not_active IP Right Cessation
- 2009-05-27 IL IL199019A patent/IL199019A/en active IP Right Grant
- 2009-06-16 EC EC2009009436A patent/ECSP099436A/es unknown
- 2009-06-17 CO CO09062879A patent/CO6210721A2/es active IP Right Grant
-
2010
- 2010-04-30 US US12/771,661 patent/US8129391B2/en active Active
- 2010-05-20 HK HK10104975.9A patent/HK1139137A1/xx unknown
-
2011
- 2011-07-11 HR HR20110520T patent/HRP20110520T1/hr unknown
- 2011-07-20 CY CY20111100721T patent/CY1111721T1/el unknown
-
2012
- 2012-01-26 US US13/359,008 patent/US8604022B2/en active Active
-
2013
- 2013-11-13 US US14/078,918 patent/US20140066455A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,381 patent/US9688640B2/en active Active
-
2017
- 2017-05-26 US US15/606,141 patent/US10301267B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110520T1 (hr) | Acilaminopirazoli kao inhibitori fgfr | |
JP2010513444A5 (hr) | ||
CA2731146C (en) | 3,4-diarylpyrazoles as protein kinase inhibitors | |
JP4310109B2 (ja) | ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物 | |
ES2629414T3 (es) | Derivados de tiazol | |
JP5412429B2 (ja) | 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物 | |
SI3083586T1 (en) | The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products | |
JP2019512482A5 (hr) | ||
HRP20201746T1 (hr) | Aromatski derivati sulfonamida | |
CA2756873C (en) | Imidazo [2,1-b] [1,3,4] thiadiazole derivatives | |
HRP20170019T1 (hr) | Novi pirol-inhibitori od reduktaze s-nitrozoglutationa kao terapeutska sredstva | |
SI3177619T1 (en) | 2- (morpholin-4-yl) -1,7-naphthyridines | |
RU2016108753A (ru) | Ингибиторы ферментов | |
PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
JP2019519484A5 (hr) | ||
CA2716365A1 (en) | Heterocyclic urea derivatives and methods of use thereof-211 | |
JP2016523911A5 (hr) | ||
JP2013528591A5 (hr) | ||
HRP20160421T1 (hr) | Derivat azola | |
AU2005207946A1 (en) | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer | |
RU2007100136A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
IL156751A (en) | Transformed alkylamines and pharmaceutical preparations that include them | |
CA2418273A1 (en) | Urea compounds and methods of uses | |
CA2554310A1 (en) | Benzamide derivatives and their use as glucokinase activating agents | |
NO339260B1 (no) | Pyridylforbindelser som inhiberer hedgehog-signalveien, fremgangsmåte for fremstilling derav, preparat der av, anvendelse derav for fremstilling av et medikament for behandling av kreft eller inhibering av angiogenese eller hedgehog-signalveien hos et pattedyr |